1 / 20

Plasma Lipids at diagnosis of Type 2 Diabetes

UKPDS. MEN. WOMEN. Type 2. Control. Type 2. Control. N. 2139. 52. 1574. 143. TC mmol/l (mg/dl). 5.5 (213). 5.3 (205). 5.8 (224). 5.6 (217). LDL-C mmol/l (mg/dl). 3.6 (139). 3.4 (132). 3.9 (151). 3.5 (135). HDL-C mmol/l (mg/dl). 1.0 (39). 1.1 (43). 1.1 (43). 1.4 (55).

acacia
Download Presentation

Plasma Lipids at diagnosis of Type 2 Diabetes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. UKPDS MEN WOMEN Type 2 Control Type 2 Control N 2139 52 1574 143 TC mmol/l (mg/dl) 5.5 (213) 5.3 (205) 5.8 (224) 5.6 (217) LDL-C mmol/l (mg/dl) 3.6 (139) 3.4 (132) 3.9 (151) 3.5 (135) HDL-C mmol/l (mg/dl) 1.0 (39) 1.1 (43) 1.1 (43) 1.4 (55) TG mmol/l (mg/dl) 1.8 (159) 1.2 (103) 1.8 (159) 1.1 (95) Plasma Lipids at diagnosis of Type 2 Diabetes UKPDS study group, Diabetes Care 1997; 20: 1683-1687

  2. 160 140 Diabetes No diabetes 120 100 CV mortality per10.000 person years 80 60 40 20 0 mmol/L < 4.7 4.7-5.1 5.2-5.7 5.8-6.2 6.3-6.7 6.8-7.2 ³ 7.3 total cholesterol MRFIT: DM type 2 and cardiovascular mortality Stamler J et al. Diabetes Care 16(2): 434 - 444, 1993

  3. No Diabetes Diabetes LDL particles LDL particles ‘Normal’ LDL-cholesterol ‘Normal’ LDL-cholesterolhowever: LDL-apo B LDL-apo B/CE LDL-CE/TG Diabetes and DyslipidemiaLDL- size and diabetes High Low CHD risk M. Austin JAMA 1988; 269: 1916

  4. LDL diameter (nm) 28 R= -0.88 27 26 25 24 23 0 1 2 3 4 5 6 Plasma TG (mmol/L) LDL diameter vs plasma TG Scheffer et al; Clin Chem 1997;43:1904-12

  5. Atherosclerosis“The Overall Picture”

  6. Clinical Trials of Lipid Therapy in Diabetic Subjects (subgroup analysis) Studyjournal N LDL-C Baseline CHDlowering LDL-C reductionPrimary preventionHelsinki HS Diabetes 135 -6 % 4,9 mmol/l -60 % (ns) Care 1992 191 mg/dlAFCAPS/TEXCAPS JAMA 1998 264 -25% 3.9 mmol/l -43 % (ns) 150 mg/dl Secondary preventionCARE NEJM 1996 586 -28 % 3,5 mmol/l -25 % (p=0.05)137 mg/dl4S Diabetes 202 -36 % 4,8 mmol/l -55 % (p=0.002)Care 1997 186 mg/dl Haffner Diabetes Care; 1: 1998

  7. Number of prevened Fatal and non fatal MI’s Expected fatal and non fatal Ml’s patients with diabetes patients without diabetes Risk Reduction4 S trial Estimated CHD reduction after treating 100 CHD patients for 6 years 49 24 29 9 Pyörälä K et al. Diabetes Care 20(4): 614 - 620, 1997

  8. Management Of Lipids in Patients with Diabetes Mellitus Type 2

  9. Risk Factor Management General Rules • Risk factor assessment • Setting goals for therapy • Primary prevention • Secondary prevention • Specific modalities of therapy based on impact and practicality • Lipid management • Asperin use • Blood pressure control • Smoking cessation • Glycemic control • Weight management

  10. Suggested Risk FactorTarget Levels RISK FACTOR GOAL Blood pressure 130/80 mm Hg HbA1c <7.5% BMI <25kg/m2 Waist circumference males <98 cm females <88 cm Urinary albumin excretion <30 mg/day

  11. Lipid Management Glycaemic Control • Glucose lowering in untreated diabetics will improve the lipidprofile • Better glycaemic control, independent of mode of therapy, further improves the lipidprofile • Unfortunately target lipid levels are not achieved with good glycaemic control in most patients

  12. Lipid Targets for Patients with Type 2 Diabetes Mellitus Target (mg/dl)Plasma Lipid Acceptable IdealTriglycerides 200 150 Total cholesterol 200 170 LDL-cholesterol 130 100 Non-HDL-cholesterol 160 130 HDL-cholesterol 35 45 • Haffner SM. Management of dyslipidemia in adults withdiabetes [American Diabetes Association position state-ment].Diabetes Care. 1998;21:160-178. • Garg A. Treatment of diabetic dyslipidemia. Am JCardiol. 1998;81(4A):47B-51B.

  13. B-mode US B-mode US B-mode US Patient population • FH • LDL-C >212 mg/dL • TG <400 mg/dL Atorvastatin 80 mg Simvastatin 40 mg 2 years ASAP Study Design 326patients • Primary efficacy parameter: • Change in carotid and femoral IMT Patients are initiated on atorvastatin 40 mg or simvastatin 20 mg. Doses are doubled at Week 4

  14. Atorvastatin mmol/l mg/dl TC 9.99 386 TG 1.86 165 HDL-C 1.17 45 LDL-C 8.00 309 Simvastatin mmol/l mg/dl 10.27 396 1.85 164 1.16 45 8.33 322 Baseline Lipid Profile

  15. Atorvastatin (80 mg) TC - 42% 5.73 mmol/l 221 mg/dl TG - 29% 1.23 mmol/l 109 mg/dl HDL +13% 1.32 mmol/l mg/dl LDL - 51% 3.88 mmol/l 150 mg/dl Simvastatin (40 mg) - 34% 6.71 mmol/l 259 mg/dl -17 % 1.41 mmo/l 125 mg/dl + 13 % 1.30 mmol/l 50 mg/dl - 41 % 4.81 mmol/l 186 mg/dl Cholesterol lowering (n=325)

  16. Change in IMT after 1 and 2 years

  17. Atorvastatin Progression female 35.1 % male 31.8 % Regression female 64.9 % male 68.2 % Simvastatin Progression female 57.4 % male 58.1 % Regression female 42.5 % male 41.9 % % patients with progression

  18. Priorities for Treatment Strategiesof Diabetic Dyslipidemia • LDL-cholesterol lowering • Triglyceride lowering • HDL-cholesterol raising • Other approaches • Non-HDL cholesterol • Apo B • Remnants

  19. Future Directions Ongoing Trials with Lipid Lowering Focus HPS Simvastatin CARDS Atorvastatin ASPEN Atorvastatin LDS Cerivastatin / Fenofibrate DAIS Fenofibrate FIELD Fenofibrate

More Related